EmmanuelleMClerisme-BeatyMD

Critical Care Medicine, Pleural Disease

Physician

Are you Dr. Clerisme-Beaty?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting!
Read the latest clinical news, personalized to your specialty.

Dr. Emmanuelle Clerisme-Beaty, MD is a pulmonologist in Sandy Hook, Connecticut. She is currently licensed to practice medicine in Connecticut and Maryland.

Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine, 2002 - 2005
Yale School of MedicineClass of 2002

PubMed

14 citations
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.
Robin R. Deterding, Matthias Griese, Gail H. Deutsch, David Warburton, Emily M. DeBoer
ERJ Open Research. 2021-04-01
105 citations
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSC...
Kristin B. Highland, Oliver Distler, Masataka Kuwana, Yannick Allanore, Shervin Assassi
The Lancet. Respiratory Medicine. 2021-01-01
145 citations
The natural history of progressive fibrosing interstitial lung diseases.
Kevin K. Brown, Fernando J. Martinez, Simon L.F. Walsh, Victor J. Thannickal, Antje Prasse
The European Respiratory Journal. 2020-01-01

Newly Published Trial Results Showed Spesolimab Significantly Improved Signs and Symptoms of Flare in Rare, Life-Threatening Skin Disease, Generalized Pustular PsoriasisDecember 23rd, 2021
Newly Published Trial Results Showed Spesolimab Significantly Improved Signs and Symptoms of Flare in Rare, Life-Threatening Skin Disease, Generalized Pustular PsoriasisDecember 22nd, 2021